PROK
ProKidney Corp - Class A (PROK)
Healthcare • NASDAQ • $1.86-1.06%
- Symbol
- PROK
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.86
- Daily Change
- -1.06%
- Market Cap
- $561.65M
- Trailing P/E
- N/A
- Forward P/E
- -2.55
- 52W High
- $7.13
- 52W Low
- $0.54
- Analyst Target
- $6.25
- Dividend Yield
- N/A
- Beta
- 1.75
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Company websiteResearch PROK on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.